Clinical trials: HIV Lipodystrophy Syndrome
HIV Infections, Dyslipidemias
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose…
- Conditions
- HIV Infections, Dyslipidemias, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT00192621
- Testing
- Combivir (zidovudine [AZT] / lamivudine [3TC]), Kaletra (lopinavir [LPVr])
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections, HIV Metabolic Cardiovascular Syndrome
Yoga for the Management of HIV-Metabolic Syndromes
We are testing the safety and efficacy of a 16-wk yoga lifestyle intervention on oral glucose tolerance, fasting lipid/lipoprotein levels, body composition, cardiovascular function, quality of life, CD4+ T-cell counts and viral…
- Conditions
- HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes
- Trial name
- NCT00627380
- Testing
- Yoga lifestyle intervention, Standard of care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
HIV Infection, HIV Infections
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
The aim of this study is to measure the prevention of lipoatrophy in patients treated with Lopinavir/R in monotherapy versus ZDV + 3TC + ABC
- Trial name
- KALIPO (NCT00865475)
- Testing
- AZT+3TC+ABV (Trizivir), Switching to LPV/r monotherapy (Kaletra)
- Where
- 7 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections
Endothelial Dysfunction as a Risk Factor in HIV Study
Highly active antiretroviral therapy (HAART) has proven effective in altering the natural history of HIV infection in many patients. However, this therapy may not be sustainable because of the toxicities of the medications.
- Trial name
- NCT00039663
- Testing
- Pravastatin, Gemfibrozil, Rosiglitazone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hiv, HIV Infections
Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
Randomized controlled parallel open-label study in persons living with HIV. The aim is to study weight changes in patients switching from a dolutegravir and tenofovir disoproxil containing regimen to either a dolutegravir or…
- Conditions
- Hiv, HIV Infections, HIV Lipodystrophy, Osteoporosis
- Trial name
- AVERTAS-2 (NCT04903847)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- Where
- 5 sites in Denmark
- Volunteers
- 126 people
- Sponsor
- Thomas Benfield
HIV-1-infection, Antiviral Drug Adverse Reaction
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir…
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities
- Trial name
- NCT04340388
- Testing
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Augusta University
Facial Lipoatrophy
Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)
5 year, open-label study to evaluate safety of SCULPTRA on the signs of lipoatrophy of the face in at least 100 evaluable subjects with human immunodeficiency virus.
- Trial name
- FACES (NCT00360932)
- Testing
- SCULPTRA (poly-L-lactic acid injection)
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Bausch Health Americas, Inc.
HIV Infections, Lipoatrophy
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV…
- Trial name
- NCT00307164
- Testing
- NucleomaxX
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 167 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lipodystrophy, HIV Infection
Metabolic Abnormalities in HIV-infected Persons
The purpose of this study is to examine the relationship between insulin resistance and changes in body fat distribution in HIV-infected persons.
- Trial name
- NCT01612858
- Testing
- Metformin, Pioglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tufts Medical Center
HIV Lipodystrophy
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and…
- Trial name
- NCT00362440
- Testing
- Leptin, Pioglitazone or metformin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Lipodystrophy
Raltegravir Therapy for Women With HIV and Fat Accumulation
Ritonavir-boosted protease inhibitor (PI) regimens have become a backbone for treatment of people with HIV. However, adverse drug effects, particularly lipodystrophy/lipoatrophy are closely associated with these regimens.
- Trial name
- NCT00656175
- Testing
- raltegravir
- Where
- 5 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
Lipodystrophy, HIV Infections
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
- Trial name
- NCT00608023
- Testing
- Tesamorelin
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 263 people
- Sponsor
- Theratechnologies
HIV Infections, Lipodystrophy
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of anti-HIV (Human Immunodeficiency Virus) drug that can be an important part of an HIV treatment regimen.
- Conditions
- HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00119405
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Lipodystrophy
Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy
The aim of this study is to evaluate the efficacy for the recovery of peripheral fat of lopinavir/ritonavir in monotherapy versus abacavir/lamivudine and lopinavir/ritonavir in subjects who developed lipoatrophy while receiving…
- Conditions
- HIV Infection, Lipodystrophy, HIV Infections
- Trial name
- KRETA (NCT00865007)
- Testing
- Monotherapy (Lopinavir/ritonavir), Monotherapy (Lopinavir/ritonavir) + ABC/3TC
- Where
- 11 sites in Spain
- Volunteers
- 88 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections
Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
The objective is to analyse the changes in the adipose tissue hystological features and the adipogenesis gene expression and related to inflammation after 48 and 96 weeks after the change from AZT+3TC+ABC (Trizivir®) to a…
- Trial name
- BIOKAL (NCT01031849)
- Testing
- Kaletra
- Where
- 2 sites in Spain
- Volunteers
- 7 people
- Sponsor
- Ines Perez
HAART-induced Lipodystrophy and Metabolic Syndrome
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
The purpose of this study is to examine whether replacing leptin to normal levels can reverse the changes in fat distribution, lipid profile, and other metabolic problems associated with highly active antiretroviral therapy…
- Trial name
- NCT00140244
- Testing
- r-metHuLeptin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
Cardiovascular Diseases
Strength Training With Vascular Occlusion in Patients Harboring With HIV/Aids
The use of antiretroviral therapy (ART) could prevent depression of the immune system of patients harboring with Human Immunodeficiency Virus (HIV), providing increased life expectancy, changing the classification of HIV / AIDS…
- Trial name
- NCT02783417
- Testing
- Strength Training
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- University of Sao Paulo